Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Sponsor
GlaxoSmithKline (Industry)
Overall Status
Terminated
CT.gov ID
NCT03345407
Collaborator
(none)
943
162
6
13.4
5.8
0.4
Study Details
Study Description
Brief Summary
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a range of doses [up to 750 micrograms (µg)] compared with placebo. The study consists of a Screening Period, a 12-Week Treatment Period and a 12-Week Post-Treatment Follow-Up Period. Approximately 1,250 subjects with an acute moderate or severe exacerbation of COPD requiring standard of care (SoC) therapy will be randomized in this double-blind study. Subjects will be randomized to receive different doses of nemiralisib or placebo via ELLIPTA® inhaler. The total duration of study participation is approximately 6 months (170 days). ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
943 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subjects will be randomized to receive either nemiralisib (50-750 µg) or placebo in a parallel group.Subjects will be randomized to receive either nemiralisib (50-750 µg) or placebo in a parallel group.
Masking:
Double (Participant, Investigator)
Masking Description:
This will be a double blind, sponsor- open study.
Primary Purpose:
Treatment
Official Title:
A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Actual Study Start Date
:
Nov 28, 2017
Actual Primary Completion Date
:
Jan 10, 2019
Actual Study Completion Date
:
Jan 10, 2019
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: placebo once daily Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Placebo ELLIPTA
Placebo will be administered via oral inhalation route once daily in the morning.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
| Experimental: Nemiralisib 50 µg once daily Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Nemiralisib ELLIPTA 50 µg
Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
| Experimental: Nemiralisib 100 µg once daily Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Nemiralisib ELLIPTA 100 µg
Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
| Experimental: Nemiralisib 250 µg once daily Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Nemiralisib ELLIPTA 250 µg
Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
| Experimental: Nemiralisib 500 µg once daily Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Nemiralisib ELLIPTA 500 µg
Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
| Experimental: Nemiralisib 750 µg once daily Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed. |
Drug: Nemiralisib ELLIPTA 750 µg
Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
Drug: Albuterol (Salbutamol) MDI or nebules
Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
Drug: Standard of care therapy
SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 84 Measured Post Bronchodilator [Baseline and Day 84]
FEV1 is maximal amount of air exhaled forcefully from lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10-30 minutes after participant was administered 4 inhalations of albuterol (salbutamol) via MDI using spacer/valved-holding chamber or via one nebulized treatment. Post-bronchodilator Baseline FEV1 is latest FEV1 measured prior to first dose of study treatment and post-bronchodilator. Change from Baseline in clinic visit trough FEV1 at Day 84 measured post-bronchodilator is FEV1 measured prior to dosing and post-bronchodilator on Day 84 minus post-bronchodilator Baseline FEV1. Bayesian repeated measure model adjusted for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender was used. Posterior adjusted median change from Baseline and 95% highest posterior density (HPD) credible interval (CrI) was presented.
Secondary Outcome Measures
- Rate of Moderate and Severe Exacerbations Over 12-week Treatment Period [Up to Week 12]
Moderate COPD exacerbations are defined as worsening symptoms of COPD treated with short-acting bronchodilators (SABDs) plus antibiotics and/or oral/systemic corticosteroids. Severe COPD exacerbations are defined as worsening symptoms of COPD that require hospitalization or visit to the emergency room. Severe exacerbation may also be associated with acute respiratory failure. Rate of exacerbations was analyzed using Bayesian Poisson model adjusting for length of on-treatment follow-up, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Posterior median exacerbation rate and 95% HPD CrI has been presented.
- Number of Participants With Time to Next Moderate/Severe Exacerbation Following Index Exacerbation [Up to Week 12]
Number of participants with time to next (on-treatment) moderate/severe exacerbation following index exacerbation during the 12-Week Treatment Period was defined as time from the date of randomization until the date of onset of the first moderate/severe exacerbation whilst on study treatment. Participants who did not have an exacerbation whilst on study treatment were censored at the date of their last dose of study treatment. Time to next exacerbation was analyzed using a Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender.
- Change From Baseline in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator [Baseline and Days 14, 28, 56 (pre and post bronchodilaor), 84 (pre-bronchodilator) and at hospital discharge (maximum 24 Weeks)]
Pulmonary function was measured by FEV1, defined as maximal amount of air exhaled forcefully from the lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10-30 minutes after participant was administered with 4 inhalations of albuterol via MDI using a spacer/valved-holding chamber or via 1 nebulized treatment. Pre-bronchodilator and post-bronchodilator Baseline FEV1 is latest FEV1 measured prior to first dose of study treatment and pre-bronchodilator and post-bronchodilator, respectively. Change from Baseline in clinic visit trough FEV1 at Days 14, 28, 56 and 84 measured pre-bronchodilator is defined as FEV1 measured prior to dosing and pre-bronchodilator on Days 14, 28, 56 and 84 minus pre-bronchodilator Baseline FEV1.
- Change From Hospital Discharge in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator [Baseline and pre- and post-bronchodilator on Days 14, 28, 56 and 84]
Pulmonary function was measured by FEV1, defined as maximal amount of air exhaled forcefully from the lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10 to 30 minutes after participant was administered with 4 inhalations of albuterol via MDI using a spacer/valved-holding chamber or via 1 nebulized treatment. Pre-bronchodilator and post-bronchodilator Baseline FEV1 is defined as latest FEV1 measured prior to first dose of study treatment and pre-bronchodilator and post-bronchodilator, respectively. Change from hospital discharge in clinic visit trough FEV1 at Days 14, 28, 56 and 84 measured pre- and post-bronchodilator is defined as FEV1 measured prior to dosing and pre- and post-bronchodilator on Days 14, 28, 56 and 84 minus pre and post-bronchodilator Baseline FEV1.
- Percentage of Participants Achieving the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Definition of Recovery From the Index Exacerbation [Days 14, 28, 56 and 84]
EXACT patient-reported outcome (EXACT-PRO), 14-item instrument to capture occurrence, frequency, severity, and duration of exacerbations using an electronic diary (eDiary). Total score ranges from 0-100, higher score indicates more severe condition. Participants were required to complete EXACT-PRO every evening; however, on the day of randomization it was to be completed in the morning. Response was decrease in rolling average EXACT Total Score >=9 points from maximum observed value, sustained for >=7 days, with first of 7 days defined as recovery day. Analysis was performed using Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender.
- Number of Participants With Time to Recovery From Index Exacerbation Using EXACT- PRO Tool [From randomization to Week 12]
Time to EXACT-defined recovery from index exacerbation is defined as time from the date of randomization until date of the first EXACT-defined recovery day during the 12-Week Treatment Period. EXACT-defined recovery from the index exacerbation is defined as a decrease in the Rolling Average EXACT total Score >=9 points from the Maximum Observed Value, sustained for >=7 days, with the first of the 7 days defined as the recovery day. Analysis was performed using a Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Number of participants reporting events is presented.
- Mean Severity of Subsequent Health Care Resource Use (HCRU) Exacerbations Defined by EXACT [Up to Week 12]
Severity of subsequent HCRU-defined exacerbations defined by EXACT was defined as the highest EXACT Total Score (not using the 3-day Rolling Average) during the period from date of onset of the subsequent HCRU-exacerbation until date of EXACT-defined recovery of subsequent exacerbation. EXACT-PRO, 14-item instrument to capture occurrence, frequency, severity, and duration of exacerbations using an eDiary. Total score ranges from 0-100, higher score indicates more severe condition. For participants with more than one subsequent exacerbation, severity was calculated for each subsequent exacerbation.
- Percentage of Responders Using the COPD Assessment Test (CAT) on Treatment Days 28, 56, and 84, and Following EXACT Defined Recovery From the Index Exacerbation [Days 28, 56 and 84]
The CAT is a short, self-completed, 8-item questionnaire, each item was rated on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment). The total CAT score is calculated by summing the scores of all items and ranges from 0 to 40, higher scores indicating severe condition. The percentage of responders using the CAT is defined as number of participants with a decrease from Baseline in CAT Total Score >=2 on or before Days 28, 56 and 84 divided by total number of participants in the MITT population. Percentage of responders using CAT was derived only for participants with a Baseline CAT Total Score >=2. Analysis was performed using a separate Bayesian logistic regression for each time point adjusting for treatment group, smoking status at baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender.
- Change From Baseline in CAT Total Score [Baseline and at Days 28, 56 and 84]
The CAT is a short, self-completed, 8-item questionnaire, each item was rated on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment). The total CAT score was calculated by summing the scores of all items and ranges from 0 to 40, higher scores indicating more severe condition. Baseline (Day 1) is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in CAT Total Score is defined as CAT Total Score on Days 28, 56 and 84 minus Baseline CAT Total Score. Analysis was performed using Bayesian repeated measures model adjusting for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Posterior adjusted median change from Baseline and 95% HPD CrI has been presented.
- Percentage of Responders on the St. George's Respiratory Questionnaire (SGRQ) Total Score as Measured by the SGRQ for COPD Participants (SGRQ-C) at Days 28, 56, and 84 [Days 28, 56 and 84]
SGRQ-C is a 40-item questionnaire designed specifically to focus on COPD participants and was scored equivalent to the SGRQ Total Score, ranging from 0 to 100, where higher scores reflect worse health-related quality of life. The percentage of responders on the SGRQ Total Score was derived for participants with a Baseline SGRQ Total Score >=4. Percentage of responders on the SGRQ Total Score is defined as number of participants with a decrease from Baseline in SGRQ Total Score >=4 on or before Days 28, 56 and 84 divided by total number of participants in the MITT population. Analysis was performed using a separate Bayesian logistic regression for each time point adjusting for treatment group, smoking status at baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender.
- Change From Baseline in SGRQ Total Score at Days 28, 56 and 84 [Baseline and Days 28, 56 and 84]
SGRQ-C is a 40-item questionnaire designed specifically to focus on COPD participants and was scored equivalent to SGRQ Total Score, ranging from 0 to 100, where higher scores reflect worse health-related quality of life. Scores on a scale were calculated as 100 multiplied by summed weights from positive items in questionnaire divided by sum of weights of all items in questionnaire. Baseline (Day 1) is defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in SGRQ Total Score is defined as SGRQ Total Score on Days 28, 56 and 84 minus Baseline SGRQ Total Score. Analysis was performed using Bayesian repeated measures model adjusting for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender. Posterior adjusted median change from Baseline and 95% HPD CrI was presented
- Mean Number of Occasions of Rescue Medication Use Per Day [Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of treatment and over the Week 12 treatment period]
Albuterol (Salbutamol) MDI or nebules was used as a rescue medication. Rescue medication use was recorded as the number of occasions of rescue medication use each day. The mean number of occasions of rescue medication use per day is defined as sum of the number of occasions of rescue medication use each day within the time-period divided by the total number of days with non-missing values within the time-period. Over the 12-Week treatment period is defined as Day 1 to Day of last dose.
- Percentage of Rescue-free Days [Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of treatment and over the Week 12 treatment period]
Albuterol (Salbutamol) MDI or nebules was used as a rescue medication. Percentage of Rescue-Free Days is defined as sum of the number of days where the number of occasions of rescue medication use is zero within the time-period divided by total number of days with non-missing values within the time-period multiplied by 100 where the time-period is defined as follows: Week 1: Day 1-7; Week 2: Day 8 - 14; Week 3: Day 15-21; Week 4: Day 22-28; Week 5: Day 29-35; Week 6: Day 36-42; Week 7: Day 43-49; Week 8: Day 50-56; Week 9: Day 57-63; Week 10: Day 64-70; Week 11: Day 71-77; Week 12: Day 78 to Day of last dose; Over the 12-Week: Day 1 to Day of last dose.
- Plasma Concentration of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed for concentrations of Nemiralisb. Pharmacokinetic (PK) Population consists of all participants in the Safety population who had at least 1 non-missing PK assessment (Non-quantifiable [NQ] values will be considered as non-missing values). Participants were summarized according to the treatment that they actually received.
- Number of Participants Reporting Non-serious Adverse Events (Non-SAEs), SAEs and AE of Special Interest (AESI) [Up to Week 24]
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect and other important medical events. Safety Population consists of all randomized participants who received at least one dose of study treatment. Participants were summarized according to treatment that they actually received.
- Number of Participants With Worst Case Post Baseline Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP) and Pulse Rate [Up to Week 16]
The DBP, SBP and pulse rate were measured with participants seated at least 5 minutes before the assessments. Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value.
- Number of Participants With Abnormal Electrocardiogram (ECG) Findings [Screening, Days 14, 84, 112 and at early withdrawal]
A single 12-lead ECG with a 15-second rhythm strip was obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and corrected QT (QTc) intervals. Abnormal ECG findings are presented.
- Number of Participants With Worst Case Post Baseline Clinical Chemistry Values [Upto Week 16]
Blood samples were collected for the analysis of clinical chemistry parameters including: blood urea nitrogen (BUN), creatinine (Crt), glucose (Glu), potassium (Pot), sodium (Sod), calcium (Cal), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total and direct bilirubin, total protein and albumin (Alb). Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value.
- Number of Participants With Worst Case Post Baseline Hematology Values [Upto Week 16]
Blood samples were collected for the analysis of hematology parameters including: platelets (Pla), red blood cells count, Hemoglobin (Hb), Hematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), percentage reticulocytes, neutrophils (Neu), lymphocytes (Lym), monocytes, eosinophils, leukocytes (Leu) and basophils. Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value.
- Number of Participants Reporting COPD Exacerbations [Up to Week 16]
Participants reporting acute COPD exacerbations during the study period has been presented.
Other Outcome Measures
- Area Under the Concentration Time Curve (AUC) From Time Zero to 24 Hours [AUC(0-24)] of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed.
- AUC From Time Zero to Time 't' [AUC(0-t)] of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed.
- Maximum Observed Plasma Drug Concentration (Cmax) of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed.
- Time to Reach Cmax (Tmax) of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed.
- Plasma Drug Concentration at Pre-dose (Ctrough) of Nemiralisib [Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28]
Plasma samples were collected at indicated time points and analyzed.
Eligibility Criteria
Criteria
Ages Eligible for Study:
40 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
40 to 80 years of age, inclusive, at Screening (Visit 1).
-
An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [ global initiative for chronic obstructive lung disease (GOLD), 2017] as follows: "Chronic obstructive pulmonary disease is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases."
-
Current or former cigarette smoker with a history of cigarette smoking of >=10 pack-years. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Screening (Visit 1). Number of pack years = (number of cigarettes per day / 20) x number of years smoked).
-
Acute exacerbation of COPD requiring an escalation in therapy to include oral/systemic corticosteroid(s) (prednisone 40 mg/day or equivalent) for 5 days and antibiotic(s) for 7 days; the dose and/or duration of prednisone (40 mg/day or equivalent) and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice. Acute exacerbation to be confirmed by an experienced physician and to represent a recent worsening of at least two major and one minor symptoms, one major and two minor symptoms, or all 3 major symptoms. Major symptoms include subjective increase in dyspnea, increase in sputum volume or change in sputum color. Minor symptoms include increased cough, increased wheeze, sore throat, colds or fever (oral temperature >37.5 degree Celsius) without other cause.
-
Body weight >=45 kilogram (kg) and body mass index (BMI) within the range 16 - 35 kg per meter square (kg/m^2) (inclusive)
-
Male and female subjects are eligible to participate in the study. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the 12-Week Double-Blind Treatment Period and for at least 5 half-lives (10 days) after the last of double-blind study treatment.
-
Capable of giving signed informed consent.
Exclusion Criteria:
-
Current diagnosis of asthma, according to the Global Initiative for Asthma (GINA, 2017). Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD.
-
Potential of hydrogen (pH) < 7.30 or the need for invasive mechanical ventilation.
-
Moderate/severe exacerbation of COPD for which SoC was started >48 hours since diagnosis.
-
A chest X-ray [or computed tomography (CT) scan] that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray (or CT scan) must be taken at Screening (Visit 1). For sites in Germany: if a chest X-ray (or CT scan) within 1 year of Screening (Visit 1) is not available, approval to conduct a diagnostic chest X-ray (CT scan) will need to be obtained from the Federal Office for Radiation Protection (BfS).
-
Clinically significant pneumonia, identified by chest X-ray (CT scan) at Screening.
-
A diagnosis of alpha 1-antitrypsin deficiency as the underlying cause of COPD, active tuberculosis, lung cancer, clinically overt bronchiectasis (Note: focal bronchiectasis is not exclusionary), sarcoidosis, pulmonary fibrosis (Note: focal fibrotic pulmonary lesions are not exclusionary), primary pulmonary hypertension, interstitial lung diseases,or any other respiratory condition that might, in the opinion of the investigator, compromise the safety of the subject or affect the interpretation of the results.
-
A history or current evidence of clinically significant and unstable disease such as cardiovascular (e.g., subjects requiring implanted cardioverter defibrillator [ICD], pacemaker requiring a rate set >60 beats per minute (bpm), uncontrolled hypertension, New Your Heart Association Class IV [NYHA, 1994], known left ventricular ejection fraction <30 percent) neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), peptic ulcer disease, or hematological abnormalities. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. (Note: subjects with adequately treated and well controlled concurrent medical conditions (e.g. hypertension or noninsulin-dependent diabetes mellitus [NIDDM]) are permitted to be entered into the study).
-
Having undergone lung volume reduction surgery or lung resection for any other reason e.g. lung carcinoma
-
Liver diseases including ALT>2x upper limit of normal (ULN); Total bilirubin >1.5xULN (Isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent); current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); Presence of hepatitis B surface antigen (HBsAg) at Screening or within 3 months prior to first dose of study treatment; Positive hepatitis C antibody test result at Screening or within 3 months prior to first dose of study treatment.
-
Positive hepatitis C ribonucleic acid (RNA) test result at Screening or within 3 months prior to first dose of study treatment.
-
Carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin are not excluded if the subject has been considered cured within 5 years since diagnosis.
-
History of allergy or hypersensitivity to any of the study medications [e.g. beta-agonists, Phosphoinositide 3-Kinase Delta (PI3Kd) inhibitors] or components of the inhalation powder (e.g., lactose). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation are excluded.
-
Strong inhibitors of cytochrome P450 3A4 (CYP3A4) including antiretrovirals including protease inhibitors; Oral antifungal treatments such as ketoconazole and itraconazole. It is recommended that posaconazole is used as the oral antifungal treatment of choice. Short courses of up to 14 days are allowed for fluconazole and voriconazole, but chronic administrations are not permitted; Antibiotics such as telithromycin and troleandomycin (macrolide). It is recommended that azithromycin is used as the macrolide antibiotic of choice. Short courses up to 14 days are allowed for mibefradil (calcium channel blocker), erythromycin and clarithromycin (including intravenous clarithromycin) but chronic administrations are not permitted; Anti-epileptic treatments; and anti-tuberculosis therapy. These medications must all have been stopped at least 14 days prior to first dose of study treatment. Use of sensitive narrow therapeutic index CYP3A4 substrates including alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus; Intravenous theophylline will be allowed but only under strict therapeutic drug monitoring for signs of theophylline toxicity as a result of co-administration with nemiralisib; Subjects may be recruited into the study already under treatment with theophylline or started on theophylline following the start of treatment and before the end of 14 days post last dose.
-
Chronic treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for >15 hours a day. Oxygen prn use (<=15 hours per day) is not exclusionary. Oxygen use during an exacerbation is permitted.
-
Chronic treatment with anti-Tumor Necrosis Factor (anti-TNF), anti-Interleukin-1 (anti-IL1), or any other immunosuppressive therapy within 60 days prior to the first dose of double-blind study treatment.
-
Clinically significant sleep apnea that requires the use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) for > 48 hours.
-
Any other investigational treatment within the following time periods prior to the first dose of double-blind study treatment in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer. Note: subjects who participated in a previously completed study and/or were withdrawn from an ongoing study that included/includes nemiralisib are excluded from participating in this study.
-
Exposure to more than 4 investigational medicinal products within 12 months prior to the first dose of double-blind study treatment in the current study.
-
A clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the exclusion criteria, outside of the reference range for the population being studied may be included if the Investigator [in consultation with the GlaxoSmithKline (GSK) Medical Monitor if required] documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
-
Abnormal, clinically significant ECG finding (e.g. myocardial Infarction or demonstrating a clinically significant arrhythmia requiring treatment) at Screening (Visit 1) or upon repeat prior to randomization.
-
QT interval corrected for heart rate according to Fridericia's formula (QTcF) >480 milliseconds (msec) for subjects with or without Bundle Branch Block, based on single QTcF value.
-
A positive test for human immunodeficiency virus (HIV) antibody at Screening.
-
Known or suspected history of alcohol or drug abuse within the last 2 years.
-
History of regular alcohol consumption defined as an average weekly intake of >28 units for males or >21 units for females within 6 months of Screening (Visit 1). One unit is equivalent to 8 grams of alcohol: a half-pint [approximately 240 milliliter (mL)] of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
-
Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
-
Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
-
Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | GSK Investigational Site | Mobile | Alabama | United States | 36608 |
| 2 | GSK Investigational Site | Colorado Springs | Colorado | United States | 80907 |
| 3 | GSK Investigational Site | Daytona Beach | Florida | United States | 32117 |
| 4 | GSK Investigational Site | Saint Petersburg | Florida | United States | 33704 |
| 5 | GSK Investigational Site | Adairsville | Georgia | United States | 30103 |
| 6 | GSK Investigational Site | Woodstock | Georgia | United States | 30189 |
| 7 | GSK Investigational Site | Columbia | Maryland | United States | 21044 |
| 8 | GSK Investigational Site | Chesterfield | Missouri | United States | 63017 |
| 9 | GSK Investigational Site | Saint Charles | Missouri | United States | 63301 |
| 10 | GSK Investigational Site | Omaha | Nebraska | United States | 68134 |
| 11 | GSK Investigational Site | Gastonia | North Carolina | United States | 28054 |
| 12 | GSK Investigational Site | Cincinnati | Ohio | United States | 45231 |
| 13 | GSK Investigational Site | Dayton | Ohio | United States | 45459 |
| 14 | GSK Investigational Site | Erie | Pennsylvania | United States | 16508 |
| 15 | GSK Investigational Site | Charleston | South Carolina | United States | 29406-7108 |
| 16 | GSK Investigational Site | Spartanburg | South Carolina | United States | 29303 |
| 17 | GSK Investigational Site | Rapid City | South Dakota | United States | 57702 |
| 18 | GSK Investigational Site | Abingdon | Virginia | United States | 24210 |
| 19 | GSK Investigational Site | Richmond | Virginia | United States | 23225 |
| 20 | GSK Investigational Site | Richmond | Virginia | United States | 23229 |
| 21 | GSK Investigational Site | Morgantown | West Virginia | United States | 26505 |
| 22 | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires | Argentina | C1414AIF |
| 23 | GSK Investigational Site | Florida | Buenos Aires | Argentina | 1602 |
| 24 | GSK Investigational Site | Mar del Plata | Buenos Aires | Argentina | 7600 |
| 25 | GSK Investigational Site | San Rafael | Mendoza | Argentina | 5600 |
| 26 | GSK Investigational Site | Rosario | Santa Fe | Argentina | 2000 |
| 27 | GSK Investigational Site | Santo Tome | Santa Fe | Argentina | 3016 |
| 28 | GSK Investigational Site | Buenos Aires | Argentina | C1280AEB | |
| 29 | GSK Investigational Site | Buenos Aires | Argentina | C1424BSF | |
| 30 | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Argentina | C1425BEN | |
| 31 | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | Argentina | C1426ABP | |
| 32 | GSK Investigational Site | Mendoza | Argentina | 5500 | |
| 33 | GSK Investigational Site | Mendoza | Argentina | M5500CCG | |
| 34 | GSK Investigational Site | Tucuman | Argentina | 4000 | |
| 35 | GSK Investigational Site | Gosford | New South Wales | Australia | 2250 |
| 36 | GSK Investigational Site | Westmead | New South Wales | Australia | 2145 |
| 37 | GSK Investigational Site | Woolloongabba | Queensland | Australia | 4102 |
| 38 | GSK Investigational Site | Woodville South | South Australia | Australia | 5011 |
| 39 | GSK Investigational Site | Clayton | Victoria | Australia | 3168 |
| 40 | GSK Investigational Site | Murdoch | Western Australia | Australia | 6150 |
| 41 | GSK Investigational Site | Edmonton | Alberta | Canada | T6G 2G3 |
| 42 | GSK Investigational Site | Sherwood Park | Alberta | Canada | T8H 0N2 |
| 43 | GSK Investigational Site | Winnipeg | Manitoba | Canada | R2H 2A6 |
| 44 | GSK Investigational Site | Windsor | Ontario | Canada | N8X 5A6 |
| 45 | GSK Investigational Site | Montreal | Quebec | Canada | H3T1E2 |
| 46 | GSK Investigational Site | Quebec City | Quebec | Canada | G1V 4G5 |
| 47 | GSK Investigational Site | St-Charles-Borromée | Quebec | Canada | J6E 2B4 |
| 48 | GSK Investigational Site | Brest cedex | France | 29609 | |
| 49 | GSK Investigational Site | Lyon | France | 69004 | |
| 50 | GSK Investigational Site | Montpellier cedex 5 | France | 34295 | |
| 51 | GSK Investigational Site | Rennes Cedex 9 | France | 35033 | |
| 52 | GSK Investigational Site | Vandoeuvre-lès-Nancy cedex | France | 54511 | |
| 53 | GSK Investigational Site | Aschaffenburg | Bayern | Germany | 63739 |
| 54 | GSK Investigational Site | Bamberg | Bayern | Germany | 96049 |
| 55 | GSK Investigational Site | Rosenheim | Bayern | Germany | 83022 |
| 56 | GSK Investigational Site | Potsdam | Brandenburg | Germany | 14467 |
| 57 | GSK Investigational Site | Darmstadt | Hessen | Germany | 64283 |
| 58 | GSK Investigational Site | Frankfurt | Hessen | Germany | 60389 |
| 59 | GSK Investigational Site | Frankfurt | Hessen | Germany | 60596 |
| 60 | GSK Investigational Site | Hannover | Niedersachsen | Germany | 30173 |
| 61 | GSK Investigational Site | Rheine | Nordrhein-Westfalen | Germany | 48431 |
| 62 | GSK Investigational Site | Warendorf | Nordrhein-Westfalen | Germany | 48231 |
| 63 | GSK Investigational Site | Koblenz | Rheinland-Pfalz | Germany | 56068 |
| 64 | GSK Investigational Site | Leipzig | Sachsen | Germany | 04103 |
| 65 | GSK Investigational Site | Geesthacht | Schleswig-Holstein | Germany | 21502 |
| 66 | GSK Investigational Site | Luebeck | Schleswig-Holstein | Germany | 23558 |
| 67 | GSK Investigational Site | Schleswig | Schleswig-Holstein | Germany | 24837 |
| 68 | GSK Investigational Site | Berlin | Germany | 12203 | |
| 69 | GSK Investigational Site | Reggio Emilia | Emilia-Romagna | Italy | 42100 |
| 70 | GSK Investigational Site | Roma | Lazio | Italy | 00133 |
| 71 | GSK Investigational Site | Roma | Lazio | Italy | 00189 |
| 72 | GSK Investigational Site | Milano | Lombardia | Italy | 20122 |
| 73 | GSK Investigational Site | Pavia | Lombardia | Italy | 27100 |
| 74 | GSK Investigational Site | Tradate (VA) | Lombardia | Italy | 21049 |
| 75 | GSK Investigational Site | Catania | Sicilia | Italy | 95123 |
| 76 | GSK Investigational Site | Messina | Sicilia | Italy | 98125 |
| 77 | GSK Investigational Site | Negrar | Veneto | Italy | 37024 |
| 78 | GSK Investigational Site | Daejon | Korea, Republic of | 35365 | |
| 79 | GSK Investigational Site | Incheon | Korea, Republic of | 21431 | |
| 80 | GSK Investigational Site | Jeonju-si, Jeollabuk-do | Korea, Republic of | 54907 | |
| 81 | GSK Investigational Site | Seongnam-si, Gyeonggi-do | Korea, Republic of | 463-707 | |
| 82 | GSK Investigational Site | Seoul | Korea, Republic of | 02559 | |
| 83 | GSK Investigational Site | Seoul | Korea, Republic of | 136-705 | |
| 84 | GSK Investigational Site | Seoul | Korea, Republic of | 137-701 | |
| 85 | GSK Investigational Site | Seoul | Korea, Republic of | 143-729 | |
| 86 | GSK Investigational Site | Seoul | Korea, Republic of | 150-713 | |
| 87 | GSK Investigational Site | Seoul | Korea, Republic of | 156-755 | |
| 88 | GSK Investigational Site | Guadalajara | Jalisco | Mexico | 44100 |
| 89 | GSK Investigational Site | Zapopan | Jalisco | Mexico | 45070 |
| 90 | GSK Investigational Site | Monterrey | Nuevo León | Mexico | 64020 |
| 91 | GSK Investigational Site | Alkmaar | Netherlands | 1815 JD | |
| 92 | GSK Investigational Site | Breda | Netherlands | 4818 CK | |
| 93 | GSK Investigational Site | Eindhoven | Netherlands | 5623 EJ | |
| 94 | GSK Investigational Site | Groningen | Netherlands | 9728 NT | |
| 95 | GSK Investigational Site | Harderwijk | Netherlands | 3844 DG | |
| 96 | GSK Investigational Site | Hoorn | Netherlands | 1624 NP | |
| 97 | GSK Investigational Site | Rotterdam | Netherlands | 3083 AN | |
| 98 | GSK Investigational Site | Utrecht | Netherlands | 3543 AZ | |
| 99 | GSK Investigational Site | Zwolle | Netherlands | 8025 AB | |
| 100 | GSK Investigational Site | Bialystok | Poland | 15-044 | |
| 101 | GSK Investigational Site | Elblag | Poland | 82-300 | |
| 102 | GSK Investigational Site | Krakow | Poland | 31-209 | |
| 103 | GSK Investigational Site | Lubin | Poland | 59-300 | |
| 104 | GSK Investigational Site | Olawa | Poland | 55-200 | |
| 105 | GSK Investigational Site | Ruda Slaska | Poland | 41-709 | |
| 106 | GSK Investigational Site | Slupsk | Poland | 76-200 | |
| 107 | GSK Investigational Site | Sosnowiec | Poland | 41-200 | |
| 108 | GSK Investigational Site | Tarnow | Poland | 33-100 | |
| 109 | GSK Investigational Site | Bucarest | Romania | 050159 | |
| 110 | GSK Investigational Site | Bucharest | Romania | 030303 | |
| 111 | GSK Investigational Site | Bucharest | Romania | 050159 | |
| 112 | GSK Investigational Site | Cluj Napoca | Romania | 400015 | |
| 113 | GSK Investigational Site | Comuna Alexandru Cel Bun | Romania | 617507 | |
| 114 | GSK Investigational Site | Iasi | Romania | 700115 | |
| 115 | GSK Investigational Site | Oradea | Romania | 410176 | |
| 116 | GSK Investigational Site | Ramnicu Valcea | Romania | 240564 | |
| 117 | GSK Investigational Site | Suceava | Romania | 720284 | |
| 118 | GSK Investigational Site | Timisoara | Romania | 300310 | |
| 119 | GSK Investigational Site | Barnaul | Russian Federation | 656 045 | |
| 120 | GSK Investigational Site | Belgorod | Russian Federation | 308007 | |
| 121 | GSK Investigational Site | Blagoveshchensk | Russian Federation | 675000 | |
| 122 | GSK Investigational Site | Chelyabinsk | Russian Federation | 454048 | |
| 123 | GSK Investigational Site | Chelyabinsk | Russian Federation | 454106 | |
| 124 | GSK Investigational Site | Ivanovo | Russian Federation | 153005 | |
| 125 | GSK Investigational Site | Kemerovo | Russian Federation | 650000 | |
| 126 | GSK Investigational Site | Nizhniy Novgorod | Russian Federation | 603011 | |
| 127 | GSK Investigational Site | Novgorod | Russian Federation | 173008 | |
| 128 | GSK Investigational Site | Novosibirsk | Russian Federation | 630102 | |
| 129 | GSK Investigational Site | Perm | Russian Federation | 614109 | |
| 130 | GSK Investigational Site | Ryazan | Russian Federation | 390039 | |
| 131 | GSK Investigational Site | Saratov | Russian Federation | 410028 | |
| 132 | GSK Investigational Site | Tomsk | Russian Federation | 634003 | |
| 133 | GSK Investigational Site | Ulyanovsk | Russian Federation | 432063 | |
| 134 | GSK Investigational Site | Voronezh | Russian Federation | 394066 | |
| 135 | GSK Investigational Site | Laredo | Cantabria | Spain | 39770 |
| 136 | GSK Investigational Site | Barcelona | Spain | 08003 | |
| 137 | GSK Investigational Site | Basurto/Bilbao | Spain | 48013 | |
| 138 | GSK Investigational Site | Cartagena (Murcia) | Spain | 30202 | |
| 139 | GSK Investigational Site | Cáceres | Spain | 10003 | |
| 140 | GSK Investigational Site | Elda (Alicante) | Spain | 03600 | |
| 141 | GSK Investigational Site | Gerona | Spain | 17007 | |
| 142 | GSK Investigational Site | Logroño | Spain | 26006 | |
| 143 | GSK Investigational Site | Madrid | Spain | 28007 | |
| 144 | GSK Investigational Site | Madrid | Spain | 28034 | |
| 145 | GSK Investigational Site | Madrid | Spain | 28046 | |
| 146 | GSK Investigational Site | Mérida (Badajoz) | Spain | 06800 | |
| 147 | GSK Investigational Site | Orihuela (Alicante) | Spain | 03314 | |
| 148 | GSK Investigational Site | Palma de Mallorca | Spain | 07198 | |
| 149 | GSK Investigational Site | Pama de Mallorca | Spain | 07010 | |
| 150 | GSK Investigational Site | Ponferrada (León) | Spain | 24411 | |
| 151 | GSK Investigational Site | Pozuelo De Alarcón/Madrid | Spain | 28223 | |
| 152 | GSK Investigational Site | Göteborg | Sweden | SE-413 45 | |
| 153 | GSK Investigational Site | Lund | Sweden | SE-221 85 | |
| 154 | GSK Investigational Site | Chesterfield | Derbyshire | United Kingdom | S40 4AA |
| 155 | GSK Investigational Site | Wishaw | Lanarkshire | United Kingdom | ML2 0DP |
| 156 | GSK Investigational Site | Blackburn | United Kingdom | BB2 3HH | |
| 157 | GSK Investigational Site | Bradford | United Kingdom | BD9 6RJ | |
| 158 | GSK Investigational Site | Edgbaston | United Kingdom | B15 2GW | |
| 159 | GSK Investigational Site | Edinburgh | United Kingdom | EH16 4SA | |
| 160 | GSK Investigational Site | Liverpool | United Kingdom | L9 7AL | |
| 161 | GSK Investigational Site | Sheffield | United Kingdom | S5 7AU | |
| 162 | GSK Investigational Site | Stockton-on-Tees | United Kingdom | TS19 8PE |
Sponsors and Collaborators
- GlaxoSmithKline
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study Documents (Full-Text)
More Information
Publications
Responsible Party:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT03345407
Other Study ID Numbers:
- 200879
- 2017-001074-42
First Posted:
Nov 17, 2017
Last Update Posted:
Jul 14, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by GlaxoSmithKline
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | This was a Phase IIb, multicenter, randomized, stratified, double-blind (sponsor open), placebo controlled parallel-group study in participants who presented with an acute moderate or severe exacerbation of chronic obstructive pulmonary disease (COPD) requiring Standard of Care (SoC). |
|---|---|
| Pre-assignment Detail | A total of 943 participants were randomized, and 938 participants who received at least one dose of study treatment were included in the modified intent to treat (MITT) Population. The study included participants enrolled from 16 countries. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Period Title: Overall Study | |||||||
| STARTED | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| COMPLETED | 244 | 19 | 79 | 81 | 75 | 73 | 233 |
| NOT COMPLETED | 32 | 3 | 12 | 11 | 15 | 16 | 45 |
Baseline Characteristics
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg | Total |
|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Total of all reporting groups |
| Overall Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 | 938 |
| Age (Years) [Mean (Standard Deviation) ] | ||||||||
| Mean (Standard Deviation) [Years] |
65.4
(7.94)
|
67.8
(7.20)
|
63.1
(7.61)
|
65.1
(7.43)
|
66.0
(6.94)
|
64.9
(8.04)
|
64.8
(7.61)
|
65.0
(7.68)
|
| Sex: Female, Male (Count of Participants) | ||||||||
| Female |
86
31.2%
|
6
27.3%
|
35
38.5%
|
29
31.5%
|
31
34.4%
|
22
24.7%
|
100
36%
|
309
32.9%
|
| Male |
190
68.8%
|
16
72.7%
|
56
61.5%
|
63
68.5%
|
59
65.6%
|
67
75.3%
|
178
64%
|
629
67.1%
|
| Race/Ethnicity, Customized (Number) [Number] | ||||||||
| American Indian or Alaska Native |
2
0.7%
|
0
0%
|
2
2.2%
|
1
1.1%
|
2
2.2%
|
2
2.2%
|
6
2.2%
|
15
1.6%
|
| Asian-East Asian Heritage |
18
6.5%
|
4
18.2%
|
7
7.7%
|
2
2.2%
|
9
10%
|
7
7.9%
|
19
6.8%
|
66
7%
|
| Asian-South East Asian Heritage |
1
0.4%
|
0
0%
|
0
0%
|
1
1.1%
|
0
0%
|
1
1.1%
|
1
0.4%
|
4
0.4%
|
| Black or African American |
2
0.7%
|
1
4.5%
|
2
2.2%
|
1
1.1%
|
0
0%
|
2
2.2%
|
6
2.2%
|
14
1.5%
|
| White-Arabic/North African Heritage |
1
0.4%
|
0
0%
|
1
1.1%
|
1
1.1%
|
0
0%
|
1
1.1%
|
0
0%
|
4
0.4%
|
| White-White Caucasian/European Heritage |
252
91.3%
|
17
77.3%
|
79
86.8%
|
86
93.5%
|
79
87.8%
|
76
85.4%
|
246
88.5%
|
835
89%
|
Outcome Measures
| Title | Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 84 Measured Post Bronchodilator |
|---|---|
| Description | FEV1 is maximal amount of air exhaled forcefully from lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10-30 minutes after participant was administered 4 inhalations of albuterol (salbutamol) via MDI using spacer/valved-holding chamber or via one nebulized treatment. Post-bronchodilator Baseline FEV1 is latest FEV1 measured prior to first dose of study treatment and post-bronchodilator. Change from Baseline in clinic visit trough FEV1 at Day 84 measured post-bronchodilator is FEV1 measured prior to dosing and post-bronchodilator on Day 84 minus post-bronchodilator Baseline FEV1. Bayesian repeated measure model adjusted for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender was used. Posterior adjusted median change from Baseline and 95% highest posterior density (HPD) credible interval (CrI) was presented. |
| Time Frame | Baseline and Day 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population consisted of all randomized participants who received at least 1 dose of study treatment.. Only those participants with data available at the specified data points were analyzed. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 215 | 16 | 72 | 75 | 69 | 58 | 216 |
| Median (95% Confidence Interval) [Liters] |
0.052
|
0.031
|
0.026
|
0.014
|
0.058
|
0.049
|
0.049
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.022 | |
| Confidence Interval |
(2-Sided) 95% -0.143 to 0.103 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 12.5 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.027 | |
| Confidence Interval |
(2-Sided) 95% -0.098 to 0.036 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 50 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.038 | |
| Confidence Interval |
(2-Sided) 95% -0.102 to 0.028 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 100 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.005 | |
| Confidence Interval |
(2-Sided) 95% -0.064 to 0.071 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 250 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.003 | |
| Confidence Interval |
(2-Sided) 95% -0.075 to 0.061 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 500 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.004 | |
| Confidence Interval |
(2-Sided) 95% -0.051 to 0.042 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior adjusted median difference and 95% HPD CrI) of Nemiralisib 750 mcg and placebo for Day 84 change from Baseline FEV1 measured post-bronchodilator has been presented. | |
| Title | Rate of Moderate and Severe Exacerbations Over 12-week Treatment Period |
|---|---|
| Description | Moderate COPD exacerbations are defined as worsening symptoms of COPD treated with short-acting bronchodilators (SABDs) plus antibiotics and/or oral/systemic corticosteroids. Severe COPD exacerbations are defined as worsening symptoms of COPD that require hospitalization or visit to the emergency room. Severe exacerbation may also be associated with acute respiratory failure. Rate of exacerbations was analyzed using Bayesian Poisson model adjusting for length of on-treatment follow-up, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Posterior median exacerbation rate and 95% HPD CrI has been presented. |
| Time Frame | Up to Week 12 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Median (95% Confidence Interval) [No.of exacerbation per 84 Days] |
0.31
|
NA
|
0.29
|
0.28
|
0.32
|
0.20
|
0.36
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median exacerbation rate ratio |
| Estimated Value | 0.92 | |
| Confidence Interval |
(2-Sided) 95% 0.60 to 1.40 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior median exacerbation rate ratio and 95% HPD CrI) of Nemiralisib 50 mcg and placebo for moderate/severe exacerbations has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median exacerbation rate ratio |
| Estimated Value | 0.89 | |
| Confidence Interval |
(2-Sided) 95% 0.57 to 1.35 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior median exacerbation rate ratio and 95% HPD CrI) of Nemiralisib 100 mcg and placebo for moderate/severe exacerbations has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median exacerbation rate ratio |
| Estimated Value | 1.01 | |
| Confidence Interval |
(2-Sided) 95% 0.65 to 1.50 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior median exacerbation rate ratio and 95% HPD CrI) of Nemiralisib 250 mcg and placebo for moderate/severe exacerbations has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median exacerbation rate ratio |
| Estimated Value | 0.63 | |
| Confidence Interval |
(2-Sided) 95% 0.37 to 1.02 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior median exacerbation rate ratio and 95% HPD CrI) of Nemiralisib 500 mcg and placebo for moderate/severe exacerbations has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median exacerbation rate ratio |
| Estimated Value | 1.13 | |
| Confidence Interval |
(2-Sided) 95% 0.85 to 1.52 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (posterior median exacerbation rate ratio and 95% HPD CrI) of Nemiralisib 750 mcg and placebo for moderate/severe exacerbations has been presented. | |
| Title | Number of Participants With Time to Next Moderate/Severe Exacerbation Following Index Exacerbation |
|---|---|
| Description | Number of participants with time to next (on-treatment) moderate/severe exacerbation following index exacerbation during the 12-Week Treatment Period was defined as time from the date of randomization until the date of onset of the first moderate/severe exacerbation whilst on study treatment. Participants who did not have an exacerbation whilst on study treatment were censored at the date of their last dose of study treatment. Time to next exacerbation was analyzed using a Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. |
| Time Frame | Up to Week 12 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Count of Participants [Participants] |
72
26.1%
|
3
13.6%
|
24
26.4%
|
25
27.2%
|
26
28.9%
|
15
16.9%
|
80
28.8%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 0.455 | |
| Confidence Interval |
(2-Sided) 95% 0.054 to 1.103 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 12.5 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 0.991 | |
| Confidence Interval |
(2-Sided) 95% 0.580 to 1.500 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 50 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 0.975 | |
| Confidence Interval |
(2-Sided) 95% 0.581 to 1.467 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 100 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.132 | |
| Confidence Interval |
(2-Sided) 95% 0.682 to 1.709 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 250 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 0.556 | |
| Confidence Interval |
(2-Sided) 95% 0.268 to 0.902 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 500 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.149 | |
| Confidence Interval |
(2-Sided) 95% 0.800 to 1.539 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison (Hazard Ratio and 95% HPD CrI) of Nemiralisib 750 mcg and placebo for time to next moderate/severe exacerbations has been presented. | |
| Title | Change From Baseline in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator |
|---|---|
| Description | Pulmonary function was measured by FEV1, defined as maximal amount of air exhaled forcefully from the lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10-30 minutes after participant was administered with 4 inhalations of albuterol via MDI using a spacer/valved-holding chamber or via 1 nebulized treatment. Pre-bronchodilator and post-bronchodilator Baseline FEV1 is latest FEV1 measured prior to first dose of study treatment and pre-bronchodilator and post-bronchodilator, respectively. Change from Baseline in clinic visit trough FEV1 at Days 14, 28, 56 and 84 measured pre-bronchodilator is defined as FEV1 measured prior to dosing and pre-bronchodilator on Days 14, 28, 56 and 84 minus pre-bronchodilator Baseline FEV1. |
| Time Frame | Baseline and Days 14, 28, 56 (pre and post bronchodilaor), 84 (pre-bronchodilator) and at hospital discharge (maximum 24 Weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 14, Pre, n=240, 20, 85, 83, 76, 76, 238 |
0.008
(0.2729)
|
0.100
(0.2511)
|
-0.021
(0.2657)
|
-0.013
(0.2509)
|
0.053
(0.2958)
|
0.041
(0.2738)
|
0.023
(0.2561)
|
| Day 14, Post, n=248, 20, 86, 83, 77, 78, 241 |
0.034
(0.2707)
|
0.075
(0.2425)
|
0.010
(0.2168)
|
-0.050
(0.2477)
|
0.054
(0.2983)
|
0.073
(0.2655)
|
0.044
(0.2216)
|
| Day 28, Pre, n=239, 20, 82, 79, 75, 71, 232 |
0.017
(0.2585)
|
0.081
(0.2661)
|
-0.034
(0.2875)
|
-0.010
(0.2333)
|
0.064
(0.2592)
|
0.016
(0.2713)
|
0.020
(0.2512)
|
| Day 28, Post, n=245, 19, 83, 81, 76, 72, 232 |
0.036
(0.2647)
|
0.059
(0.2575)
|
0.004
(0.2183)
|
-0.034
(0.2401)
|
0.049
(0.2639)
|
0.027
(0.2369)
|
0.029
(0.2307)
|
| Day 56, Pre, n=230, 20, 78, 76, 73, 67, 224 |
0.005
(0.2295)
|
-0.006
(0.2636)
|
-0.024
(0.3210)
|
0.011
(0.2415)
|
0.022
(0.2522)
|
-0.004
(0.2233)
|
-0.001
(0.2858)
|
| Day 56, Post, n=237, 19, 78, 77, 74, 69, 224 |
0.020
(0.2614)
|
-0.002
(0.2252)
|
-0.012
(0.2524)
|
0.004
(0.2373)
|
0.026
(0.2556)
|
-0.011
(0.2260)
|
0.011
(0.2470)
|
| Day 84, Pre, n=210, 17, 71, 73, 66, 58, 212 |
0.000
(0.2566)
|
0.003
(0.2232)
|
-0.049
(0.2549)
|
0.005
(0.2668)
|
0.015
(0.2739)
|
0.007
(0.2461)
|
0.010
(0.2829)
|
| Hospital discharge, Pre, n=23, 2, 8, 8, 7, 3, 22 |
0.071
(0.1586)
|
0.168
(0.2652)
|
0.108
(0.3888)
|
0.056
(0.1782)
|
0.052
(0.3481)
|
0.162
(0.1426)
|
0.075
(0.1974)
|
| Hospital discharge, Post, n=8, 2, 1, 1, 1, 0, 6 |
0.134
(0.1514)
|
0.153
(0.0933)
|
0.083
(NA)
|
-0.076
(NA)
|
0.094
(NA)
|
-0.006
(0.1079)
|
| Title | Change From Hospital Discharge in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator |
|---|---|
| Description | Pulmonary function was measured by FEV1, defined as maximal amount of air exhaled forcefully from the lungs in 1 second. Post-bronchodilator FEV1 was conducted approximately 10 to 30 minutes after participant was administered with 4 inhalations of albuterol via MDI using a spacer/valved-holding chamber or via 1 nebulized treatment. Pre-bronchodilator and post-bronchodilator Baseline FEV1 is defined as latest FEV1 measured prior to first dose of study treatment and pre-bronchodilator and post-bronchodilator, respectively. Change from hospital discharge in clinic visit trough FEV1 at Days 14, 28, 56 and 84 measured pre- and post-bronchodilator is defined as FEV1 measured prior to dosing and pre- and post-bronchodilator on Days 14, 28, 56 and 84 minus pre and post-bronchodilator Baseline FEV1. |
| Time Frame | Baseline and pre- and post-bronchodilator on Days 14, 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 14, Pre, n=20, 2, 8, 8, 6, 4, 20 |
0.082
(0.2783)
|
0.355
(0.4207)
|
0.069
(0.3012)
|
-0.049
(0.1882)
|
-0.069
(0.4905)
|
0.173
(0.5137)
|
0.002
(0.2343)
|
| Day 14, Post, n=5, 2, 1, 1, 1, 0, 5 |
0.056
(0.3372)
|
0.431
(0.5190)
|
0.119
(NA)
|
0.310
(NA)
|
-0.305
(NA)
|
-0.021
(0.1326)
|
|
| Day 28, Pre, n=37, 2, 14, 8, 10, 9, 37 |
0.026
(0.2691)
|
0.261
(0.5204)
|
0.012
(0.2910)
|
-0.085
(0.2072)
|
0.012
(0.4020)
|
0.030
(0.4029)
|
-0.046
(0.2639)
|
| Day 28, Post, n=22, 2, 8, 1, 4, 4, 22 |
0.034
(0.2779)
|
0.334
(0.5614)
|
0.130
(0.2327)
|
0.130
(NA)
|
0.009
(0.2006)
|
0.007
(0.3237)
|
-0.094
(0.2293)
|
| Day 56, Pre, n=37, 2, 14, 8, 9, 10, 36 |
0.019
(0.2282)
|
0.106
(0.6138)
|
0.019
(0.3509)
|
0.014
(0.1938)
|
-0.074
(0.3847)
|
-0.042
(0.1840)
|
-0.054
(0.2942)
|
| Day 56, Post, n=22, 2, 7, 1, 4, 5, 21 |
-0.014
(0.2896)
|
0.139
(0.6838)
|
0.042
(0.3068)
|
0.098
(NA)
|
-0.056
(0.3572)
|
-0.072
(0.1490)
|
-0.135
(0.2410)
|
| Day 84, Pre, n=37, 2, 12, 8, 7, 10, 35 |
0.007
(0.2741)
|
-0.027
(0.4554)
|
0.121
(0.2770)
|
-0.081
(0.1738)
|
-0.072
(0.4391)
|
0.043
(0.2511)
|
-0.062
(0.2816)
|
| Day 84, Post, n=22, 2, 6, 1, 4, 5, 22 |
-0.039
(0.2610)
|
0.133
(0.5162)
|
0.037
(0.3341)
|
0.108
(NA)
|
0.021
(0.3151)
|
0.006
(0.2180)
|
-0.106
(0.2956)
|
| Title | Percentage of Participants Achieving the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Definition of Recovery From the Index Exacerbation |
|---|---|
| Description | EXACT patient-reported outcome (EXACT-PRO), 14-item instrument to capture occurrence, frequency, severity, and duration of exacerbations using an electronic diary (eDiary). Total score ranges from 0-100, higher score indicates more severe condition. Participants were required to complete EXACT-PRO every evening; however, on the day of randomization it was to be completed in the morning. Response was decrease in rolling average EXACT Total Score >=9 points from maximum observed value, sustained for >=7 days, with first of 7 days defined as recovery day. Analysis was performed using Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender. |
| Time Frame | Days 14, 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 14 |
29
10.5%
|
27
122.7%
|
37
40.7%
|
29
31.5%
|
28
31.1%
|
24
27%
|
32
11.5%
|
| Day 28 |
40
14.5%
|
41
186.4%
|
52
57.1%
|
43
46.7%
|
42
46.7%
|
27
30.3%
|
42
15.1%
|
| Day 56 |
49
17.8%
|
45
204.5%
|
59
64.8%
|
52
56.5%
|
50
55.6%
|
31
34.8%
|
50
18%
|
| Day 84 |
51
18.5%
|
50
227.3%
|
59
64.8%
|
54
58.7%
|
50
55.6%
|
37
41.6%
|
54
19.4%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.01 | |
| Confidence Interval |
(2-Sided) 95% 0.21 to 2.30 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.37 | |
| Confidence Interval |
(2-Sided) 95% 0.76 to 2.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.99 | |
| Confidence Interval |
(2-Sided) 95% 0.54 to 1.61 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.94 | |
| Confidence Interval |
(2-Sided) 95% 0.50 to 1.49 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.75 | |
| Confidence Interval |
(2-Sided) 95% 0.38 to 1.25 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.16 | |
| Confidence Interval |
(2-Sided) 95% 0.77 to 1.63 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 14 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 7
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.21 | |
| Confidence Interval |
(2-Sided) 95% 0.36 to 2.69 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 8
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.53 | |
| Confidence Interval |
(2-Sided) 95% 0.82 to 2.33 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 9
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.16 | |
| Confidence Interval |
(2-Sided) 95% 0.67 to 1.79 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 10
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.12 | |
| Confidence Interval |
(2-Sided) 95% 0.63 to 1.74 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 11
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.55 | |
| Confidence Interval |
(2-Sided) 95% 0.28 to 0.88 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 12
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.08 | |
| Confidence Interval |
(2-Sided) 95% 0.72 to 1.49 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 13
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.00 | |
| Confidence Interval |
(2-Sided) 95% 0.30 to 2.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 14
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.46 | |
| Confidence Interval |
(2-Sided) 95% 0.84 to 2.27 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 15
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.15 | |
| Confidence Interval |
(2-Sided) 95% 0.65 to 1.78 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 16
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.09 | |
| Confidence Interval |
(2-Sided) 95% 0.62 to 1.67 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 17
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.49 | |
| Confidence Interval |
(2-Sided) 95% 0.26 to 0.77 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 18
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.04 | |
| Confidence Interval |
(2-Sided) 95% 0.71 to 1.42 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 19
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.08 | |
| Confidence Interval |
(2-Sided) 95% 0.32 to 2.38 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 20
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.29 | |
| Confidence Interval |
(2-Sided) 95% 0.70 to 2.00 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 21
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.12 | |
| Confidence Interval |
(2-Sided) 95% 0.63 to 1.71 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 22
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.95 | |
| Confidence Interval |
(2-Sided) 95% 0.55 to 1.48 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 23
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.56 | |
| Confidence Interval |
(2-Sided) 95% 0.31 to 0.87 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 24
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.08 | |
| Confidence Interval |
(2-Sided) 95% 0.73 to 1.47 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
| Title | Number of Participants With Time to Recovery From Index Exacerbation Using EXACT- PRO Tool |
|---|---|
| Description | Time to EXACT-defined recovery from index exacerbation is defined as time from the date of randomization until date of the first EXACT-defined recovery day during the 12-Week Treatment Period. EXACT-defined recovery from the index exacerbation is defined as a decrease in the Rolling Average EXACT total Score >=9 points from the Maximum Observed Value, sustained for >=7 days, with the first of the 7 days defined as the recovery day. Analysis was performed using a Bayesian Cox proportional hazards model adjusting for treatment group, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Number of participants reporting events is presented. |
| Time Frame | From randomization to Week 12 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Count of Participants [Participants] |
141
51.1%
|
11
50%
|
54
59.3%
|
50
54.3%
|
45
50%
|
34
38.2%
|
149
53.6%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.053 | |
| Confidence Interval |
(2-Sided) 95% 0.477 to 1.765 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.200 | |
| Confidence Interval |
(2-Sided) 95% 0.840 to 1.597 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.060 | |
| Confidence Interval |
(2-Sided) 95% 0.734 to 1.432 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.030 | |
| Confidence Interval |
(2-Sided) 95% 0.719 to 1.413 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 0.751 | |
| Confidence Interval |
(2-Sided) 95% 0.487 to 1.057 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median hazard ratio |
| Estimated Value | 1.149 | |
| Confidence Interval |
(2-Sided) 95% 0.899 to 1.426 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg was performed and posterior median hazard ratio and 95% HPD CrI has been presented. | |
| Title | Mean Severity of Subsequent Health Care Resource Use (HCRU) Exacerbations Defined by EXACT |
|---|---|
| Description | Severity of subsequent HCRU-defined exacerbations defined by EXACT was defined as the highest EXACT Total Score (not using the 3-day Rolling Average) during the period from date of onset of the subsequent HCRU-exacerbation until date of EXACT-defined recovery of subsequent exacerbation. EXACT-PRO, 14-item instrument to capture occurrence, frequency, severity, and duration of exacerbations using an eDiary. Total score ranges from 0-100, higher score indicates more severe condition. For participants with more than one subsequent exacerbation, severity was calculated for each subsequent exacerbation. |
| Time Frame | Up to Week 12 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Severity was derived for participants from MITT Population who had reported subsequent exacerbation. Only those participants with data available at specified data points were analyzed (represented by n=X in the category title). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 66 | 3 | 23 | 25 | 26 | 15 | 78 |
| Moderate/Severe, n=66, 3, 23, 25, 26, 15, 78 |
53.3
(12.16)
|
64.6
(25.20)
|
59.8
(12.82)
|
50.5
(10.76)
|
47.5
(13.95)
|
57.6
(10.30)
|
51.9
(10.78)
|
| Moderate, n=55, 3, 15, 23, 17, 10, 63 |
53.1
(11.54)
|
60.0
(26.56)
|
57.4
(11.08)
|
50.0
(11.15)
|
46.3
(14.20)
|
53.8
(9.28)
|
50.0
(10.17)
|
| Severe, n=13, 1, 9, 3, 10, 6, 20 |
54.0
(15.53)
|
83.0
(NA)
|
64.0
(15.01)
|
55.3
(5.69)
|
49.5
(13.95)
|
64.1
(8.99)
|
58.8
(10.34)
|
| Title | Percentage of Responders Using the COPD Assessment Test (CAT) on Treatment Days 28, 56, and 84, and Following EXACT Defined Recovery From the Index Exacerbation |
|---|---|
| Description | The CAT is a short, self-completed, 8-item questionnaire, each item was rated on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment). The total CAT score is calculated by summing the scores of all items and ranges from 0 to 40, higher scores indicating severe condition. The percentage of responders using the CAT is defined as number of participants with a decrease from Baseline in CAT Total Score >=2 on or before Days 28, 56 and 84 divided by total number of participants in the MITT population. Percentage of responders using CAT was derived only for participants with a Baseline CAT Total Score >=2. Analysis was performed using a separate Bayesian logistic regression for each time point adjusting for treatment group, smoking status at baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. |
| Time Frame | Days 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 28 |
32
|
36
|
34
|
39
|
38
|
34
|
25
|
| Day 56 |
63
|
50
|
73
|
61
|
69
|
55
|
61
|
| Day 84 |
70
|
55
|
78
|
65
|
72
|
60
|
66
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.22 | |
| Confidence Interval |
(2-Sided) 95% 0.35 to 2.70 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.11 | |
| Confidence Interval |
(2-Sided) 95% 0.63 to 1.77 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.41 | |
| Confidence Interval |
(2-Sided) 95% 0.77 to 2.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.28 | |
| Confidence Interval |
(2-Sided) 95% 0.71 to 2.00 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.11 | |
| Confidence Interval |
(2-Sided) 95% 0.61 to 1.75 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.70 | |
| Confidence Interval |
(2-Sided) 95% 0.46 to 0.99 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 7
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.64 | |
| Confidence Interval |
(2-Sided) 95% 0.20 to 1.41 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 8
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.53 | |
| Confidence Interval |
(2-Sided) 95% 0.84 to 2.46 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 9
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.95 | |
| Confidence Interval |
(2-Sided) 95% 0.53 to 1.48 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 10
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.36 | |
| Confidence Interval |
(2-Sided) 95% 0.74 to 2.16 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 11
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.76 | |
| Confidence Interval |
(2-Sided) 95% 0.43 to 1.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 12
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.93 | |
| Confidence Interval |
(2-Sided) 95% 0.63 to 1.27 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 13
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.54 | |
| Confidence Interval |
(2-Sided) 95% 0.16 to 1.20 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 14
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.53 | |
| Confidence Interval |
(2-Sided) 95% 0.79 to 2.56 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 15
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.83 | |
| Confidence Interval |
(2-Sided) 95% 0.46 to 1.30 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 16
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.16 | |
| Confidence Interval |
(2-Sided) 95% 0.62 to 1.86 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 17
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.65 | |
| Confidence Interval |
(2-Sided) 95% 0.36 to 1.02 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 18
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.85 | |
| Confidence Interval |
(2-Sided) 95% 0.57 to 1.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
| Title | Change From Baseline in CAT Total Score |
|---|---|
| Description | The CAT is a short, self-completed, 8-item questionnaire, each item was rated on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment). The total CAT score was calculated by summing the scores of all items and ranges from 0 to 40, higher scores indicating more severe condition. Baseline (Day 1) is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in CAT Total Score is defined as CAT Total Score on Days 28, 56 and 84 minus Baseline CAT Total Score. Analysis was performed using Bayesian repeated measures model adjusting for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. Posterior adjusted median change from Baseline and 95% HPD CrI has been presented. |
| Time Frame | Baseline and at Days 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 28, n=234, 19, 86, 80, 77, 74, 229 |
-4.7
|
-2.3
|
-4.0
|
-3.9
|
-5.1
|
-3.1
|
-4.7
|
| Day 56, n=231, 20, 78, 77, 76, 69, 222 |
-4.2
|
-1.9
|
-3.4
|
-4.5
|
-4.8
|
-3.8
|
-4.4
|
| Day 84, n=218, 17, 75, 75, 69, 62, 213 |
-4.6
|
-2.7
|
-3.5
|
-5.1
|
-4.7
|
-3.8
|
-4.2
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 2.4 | |
| Confidence Interval |
(2-Sided) 95% -0.5 to 5.2 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.7 | |
| Confidence Interval |
(2-Sided) 95% -0.8 to 2.3 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.8 | |
| Confidence Interval |
(2-Sided) 95% -0.8 to 2.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.3 | |
| Confidence Interval |
(2-Sided) 95% -2.0 to 1.2 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjacent median difference |
| Estimated Value | 1.6 | |
| Confidence Interval |
(2-Sided) 95% 0.0 to 3.3 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.0 | |
| Confidence Interval |
(2-Sided) 95% -1.1 to 1.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 7
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 2.3 | |
| Confidence Interval |
(2-Sided) 95% -0.5 to 5.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 8
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.8 | |
| Confidence Interval |
(2-Sided) 95% -0.9 to 2.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 9
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.3 | |
| Confidence Interval |
(2-Sided) 95% -1.9 to 1.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 10
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.5 | |
| Confidence Interval |
(2-Sided) 95% -2.3 to 1.0 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 11
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.4 | |
| Confidence Interval |
(2-Sided) 95% -1.2 to 2.2 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 12
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.2 | |
| Confidence Interval |
(2-Sided) 95% -1.4 to 1.0 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 13
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 1.9 | |
| Confidence Interval |
(2-Sided) 95% -1.4 to 5.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 14
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 1.1 | |
| Confidence Interval |
(2-Sided) 95% -0.7 to 2.8 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 15
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.5 | |
| Confidence Interval |
(2-Sided) 95% -2.3 to 1.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 84 was performed and posterior adjsted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 16
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.1 | |
| Confidence Interval |
(2-Sided) 95% -1.9 to 1.7 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 17
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.8 | |
| Confidence Interval |
(2-Sided) 95% -0.9 to 2.8 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 18
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 0.4 | |
| Confidence Interval |
(2-Sided) 95% -0.8 to 1.7 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
| Title | Percentage of Responders on the St. George's Respiratory Questionnaire (SGRQ) Total Score as Measured by the SGRQ for COPD Participants (SGRQ-C) at Days 28, 56, and 84 |
|---|---|
| Description | SGRQ-C is a 40-item questionnaire designed specifically to focus on COPD participants and was scored equivalent to the SGRQ Total Score, ranging from 0 to 100, where higher scores reflect worse health-related quality of life. The percentage of responders on the SGRQ Total Score was derived for participants with a Baseline SGRQ Total Score >=4. Percentage of responders on the SGRQ Total Score is defined as number of participants with a decrease from Baseline in SGRQ Total Score >=4 on or before Days 28, 56 and 84 divided by total number of participants in the MITT population. Analysis was performed using a separate Bayesian logistic regression for each time point adjusting for treatment group, smoking status at baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in the previous 12 months and gender. |
| Time Frame | Days 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 28 |
21
|
14
|
19
|
26
|
32
|
24
|
21
|
| Day 56 |
50
|
36
|
56
|
55
|
60
|
49
|
53
|
| Day 84 |
61
|
50
|
66
|
63
|
68
|
57
|
62
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.51 | |
| Confidence Interval |
(2-Sided) 95% 0.03 to 1.41 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.87 | |
| Confidence Interval |
(2-Sided) 95% 0.42 to 1.47 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.37 | |
| Confidence Interval |
(2-Sided) 95% 0.69 to 2.24 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.78 | |
| Confidence Interval |
(2-Sided) 95% 0.95 to 2.91 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.24 | |
| Confidence Interval |
(2-Sided) 95% 0.61 to 2.08 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.95 | |
| Confidence Interval |
(2-Sided) 95% 0.60 to 1.40 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 28 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 7
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.54 | |
| Confidence Interval |
(2-Sided) 95% 0.14 to 1.16 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 8
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.27 | |
| Confidence Interval |
(2-Sided) 95% 0.74 to 1.98 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 9
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.29 | |
| Confidence Interval |
(2-Sided) 95% 0.73 to 1.97 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 10
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.47 | |
| Confidence Interval |
(2-Sided) 95% 0.83 to 2.27 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 11
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.04 | |
| Confidence Interval |
(2-Sided) 95% 0.57 to 1.62 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 12
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.10 | |
| Confidence Interval |
(2-Sided) 95% 0.75 to 1.50 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 56 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 13
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.63 | |
| Confidence Interval |
(2-Sided) 95% 0.17 to 1.39 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 12.5 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 14
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.27 | |
| Confidence Interval |
(2-Sided) 95% 0.72 to 2.01 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 50 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 15
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.13 | |
| Confidence Interval |
(2-Sided) 95% 0.64 to 1.79 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 100 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 16
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.35 | |
| Confidence Interval |
(2-Sided) 95% 0.75 to 2.14 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 250 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 17
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 0.94 | |
| Confidence Interval |
(2-Sided) 95% 0.53 to 1.45 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 500 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
Statistical Analysis 18
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior median odds ratio |
| Estimated Value | 1.03 | |
| Confidence Interval |
(2-Sided) 95% 0.71 to 1.43 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and nemiralisib 750 mcg at Day 84 was performed and posterior median odds ratio and 95% HPD CrI has been presented. | |
| Title | Change From Baseline in SGRQ Total Score at Days 28, 56 and 84 |
|---|---|
| Description | SGRQ-C is a 40-item questionnaire designed specifically to focus on COPD participants and was scored equivalent to SGRQ Total Score, ranging from 0 to 100, where higher scores reflect worse health-related quality of life. Scores on a scale were calculated as 100 multiplied by summed weights from positive items in questionnaire divided by sum of weights of all items in questionnaire. Baseline (Day 1) is defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in SGRQ Total Score is defined as SGRQ Total Score on Days 28, 56 and 84 minus Baseline SGRQ Total Score. Analysis was performed using Bayesian repeated measures model adjusting for Baseline by visit interaction, treatment by visit interaction, smoking status at Baseline, region, severity of index exacerbation, number of moderate/severe exacerbations in previous 12 months and gender. Posterior adjusted median change from Baseline and 95% HPD CrI was presented |
| Time Frame | Baseline and Days 28, 56 and 84 |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Day 28, n=232, 19, 86, 78, 77, 72, 225 |
-7.7
|
-5.7
|
-8.2
|
-10.6
|
-10.9
|
-7.8
|
-7.9
|
| Day 56, n=227, 20, 78, 77, 74, 68, 219 |
-8.0
|
-3.9
|
-9.3
|
-10.7
|
-11.3
|
-8.9
|
-8.4
|
| Day 84, n=218, 17, 74, 74, 69, 60, 209 |
-9.1
|
-6.6
|
-9.3
|
-11.3
|
-10.9
|
-9.4
|
-7.9
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 2.0 | |
| Confidence Interval |
(2-Sided) 95% -4.8 to 8.3 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.5 | |
| Confidence Interval |
(2-Sided) 95% -4.0 to 3.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -2.9 | |
| Confidence Interval |
(2-Sided) 95% -6.2 to 1.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -3.2 | |
| Confidence Interval |
(2-Sided) 95% -6.7 to 0.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.1 | |
| Confidence Interval |
(2-Sided) 95% -4.0 to 3.5 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.2 | |
| Confidence Interval |
(2-Sided) 95% -2.7 to 2.3 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 28 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 7
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 4.1 | |
| Confidence Interval |
(2-Sided) 95% -2.5 to 11.0 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 8
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -1.2 | |
| Confidence Interval |
(2-Sided) 95% -4.8 to 2.5 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 9
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -2.7 | |
| Confidence Interval |
(2-Sided) 95% -6.3 to 1.1 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 10
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -3.3 | |
| Confidence Interval |
(2-Sided) 95% -7.3 to 0.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 11
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.8 | |
| Confidence Interval |
(2-Sided) 95% -4.6 to 3.0 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 12
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.4 | |
| Confidence Interval |
(2-Sided) 95% -2.9 to 2.5 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 56 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 13
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 12.5 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 2.4 | |
| Confidence Interval |
(2-Sided) 95% -4.8 to 9.4 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 12.5 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 14
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 50 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.2 | |
| Confidence Interval |
(2-Sided) 95% -4.1 to 3.6 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 50 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 15
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 100 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -2.3 | |
| Confidence Interval |
(2-Sided) 95% -6.1 to 1.8 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 100 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 16
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 250 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -1.8 | |
| Confidence Interval |
(2-Sided) 95% -5.7 to 2.3 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 250 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 17
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 500 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | -0.3 | |
| Confidence Interval |
(2-Sided) 95% -4.5 to 3.8 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 500 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
Statistical Analysis 18
| Statistical Analysis Overview | Comparison Group Selection | Placebo, Nemiralisib 750 mcg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Posterior adjusted median difference |
| Estimated Value | 1.2 | |
| Confidence Interval |
(2-Sided) 95% -1.7 to 4.0 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | Treatment comparison between placebo and Nemiralisib 750 mcg at Day 84 was performed and posterior adjusted median difference and 95% HPD CrI has been presented. | |
| Title | Mean Number of Occasions of Rescue Medication Use Per Day |
|---|---|
| Description | Albuterol (Salbutamol) MDI or nebules was used as a rescue medication. Rescue medication use was recorded as the number of occasions of rescue medication use each day. The mean number of occasions of rescue medication use per day is defined as sum of the number of occasions of rescue medication use each day within the time-period divided by the total number of days with non-missing values within the time-period. Over the 12-Week treatment period is defined as Day 1 to Day of last dose. |
| Time Frame | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of treatment and over the Week 12 treatment period |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Week 1, n=254, 21, 87, 88, 80, 79, 254 |
1.699
(1.7674)
|
2.112
(2.2977)
|
1.633
(1.4320)
|
1.926
(2.1569)
|
1.670
(1.5728)
|
1.917
(1.9298)
|
1.747
(1.7332)
|
| Week 2, n=259, 21, 88, 89, 80, 82, 252 |
1.650
(1.8711)
|
2.231
(2.7169)
|
1.469
(1.4036)
|
1.712
(2.0310)
|
1.497
(1.5700)
|
1.611
(1.7717)
|
1.587
(1.6531)
|
| Week 3, n=256, 21, 90, 88, 80, 81, 245 |
1.729
(1.8157)
|
2.021
(2.2926)
|
1.495
(1.3943)
|
1.693
(1.9679)
|
1.488
(1.6611)
|
1.742
(1.8380)
|
1.655
(1.7430)
|
| Week 4, n=250, 21, 89, 87, 81, 77, 243 |
1.684
(1.7706)
|
2.190
(2.3657)
|
1.514
(1.5022)
|
1.720
(2.0083)
|
1.489
(1.6734)
|
2.009
(2.0506)
|
1.707
(1.7512)
|
| Week 5, n=251, 20, 88, 85, 78, 76, 240 |
1.735
(1.8662)
|
2.329
(2.6394)
|
1.533
(1.5706)
|
1.750
(2.0380)
|
1.535
(1.8384)
|
1.949
(1.9685)
|
1.737
(1.8030)
|
| Week 6, n=250, 20, 86, 84, 78, 72, 234 |
1.741
(1.9543)
|
2.378
(2.6904)
|
1.382
(1.4000)
|
1.792
(2.0822)
|
1.636
(1.8042)
|
1.936
(2.0729)
|
1.780
(1.8083)
|
| Week 7, n=250, 20, 85, 83, 77, 71, 231 |
1.703
(1.9914)
|
2.479
(2.6976)
|
1.531
(1.6374)
|
1.697
(2.0769)
|
1.628
(1.8741)
|
1.899
(2.1694)
|
1.826
(1.8778)
|
| Week 8, n=250, 20, 84, 83, 77, 71, 231 |
1.656
(1.8606)
|
2.736
(3.1579)
|
1.553
(1.5884)
|
1.616
(1.9444)
|
1.572
(1.8294)
|
2.006
(2.2242)
|
1.824
(1.8397)
|
| Week 9, n=244, 20, 82, 81, 76, 71, 229 |
1.708
(1.8709)
|
2.765
(3.1104)
|
1.608
(1.7699)
|
1.658
(2.0646)
|
1.720
(1.8918)
|
1.953
(2.1838)
|
1.775
(1.8753)
|
| Week 10, n=241, 20, 81, 80, 73, 71, 227 |
1.698
(1.9023)
|
2.543
(2.8753)
|
1.589
(1.6571)
|
1.596
(1.9809)
|
1.546
(1.8824)
|
1.927
(2.1613)
|
1.705
(1.7646)
|
| Week 11, n=241, 20, 79, 80, 73, 71, 226 |
1.729
(1.9406)
|
2.164
(2.2504)
|
1.404
(1.4897)
|
1.602
(1.9435)
|
1.672
(1.9447)
|
1.926
(2.3243)
|
1.716
(1.7421)
|
| Week 12, n=240, 20, 78, 80, 73, 70, 225 |
1.666
(1.7913)
|
2.386
(2.8157)
|
1.414
(1.3920)
|
1.671
(1.9612)
|
1.712
(1.9532)
|
1.790
(2.1140)
|
1.731
(1.7245)
|
| Over 12 Week, n=273, 21, 91, 91, 86, 83, 268 |
1.684
(1.6903)
|
2.330
(2.4715)
|
1.553
(1.4044)
|
1.750
(1.9048)
|
1.620
(1.5994)
|
1.921
(1.9201)
|
1.733
(1.6618)
|
| Title | Percentage of Rescue-free Days |
|---|---|
| Description | Albuterol (Salbutamol) MDI or nebules was used as a rescue medication. Percentage of Rescue-Free Days is defined as sum of the number of days where the number of occasions of rescue medication use is zero within the time-period divided by total number of days with non-missing values within the time-period multiplied by 100 where the time-period is defined as follows: Week 1: Day 1-7; Week 2: Day 8 - 14; Week 3: Day 15-21; Week 4: Day 22-28; Week 5: Day 29-35; Week 6: Day 36-42; Week 7: Day 43-49; Week 8: Day 50-56; Week 9: Day 57-63; Week 10: Day 64-70; Week 11: Day 71-77; Week 12: Day 78 to Day of last dose; Over the 12-Week: Day 1 to Day of last dose. |
| Time Frame | Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of treatment and over the Week 12 treatment period |
Outcome Measure Data
| Analysis Population Description |
|---|
| MITT Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Week 1, n=254, 21, 87, 88, 80, 79, 254 |
34.898
(37.7118)
|
36.076
(44.3182)
|
29.849
(38.3385)
|
33.392
(39.7372)
|
32.583
(38.3577)
|
34.453
(35.9802)
|
29.779
(36.1498)
|
| Week 2, n=259, 21, 88, 89, 80, 82, 252 |
41.002
(40.9566)
|
40.819
(46.7899)
|
32.145
(41.2227)
|
43.017
(43.9884)
|
38.573
(40.3629)
|
40.595
(41.1717)
|
33.639
(38.9767)
|
| Week 3, n=256, 21, 90, 88, 80, 81, 245 |
38.204
(39.0621)
|
38.776
(44.0612)
|
31.643
(38.0943)
|
39.964
(40.3936)
|
41.191
(42.1751)
|
34.923
(40.4026)
|
33.006
(38.4986)
|
| Week 4, n=250, 21, 89, 87, 81, 77, 243 |
39.678
(40.8359)
|
35.376
(43.9405)
|
32.531
(39.0078)
|
42.202
(43.0692)
|
43.194
(41.0201)
|
30.986
(38.5941)
|
32.394
(39.0174)
|
| Week 5, n=251, 20, 88, 85, 78, 76, 240 |
38.262
(40.7807)
|
35.005
(41.8344)
|
35.552
(40.5745)
|
41.682
(41.3648)
|
41.026
(42.1584)
|
33.912
(37.9973)
|
33.168
(39.0654)
|
| Week 6, n=250, 20, 86, 84, 78, 72, 234 |
40.287
(42.2167)
|
37.870
(40.2125)
|
35.384
(40.9175)
|
41.720
(44.0117)
|
39.196
(41.6575)
|
35.519
(42.2122)
|
32.351
(39.2542)
|
| Week 7, n=250, 20, 85, 83, 77, 71, 231 |
41.373
(43.4266)
|
32.145
(43.1992)
|
35.634
(41.3319)
|
45.266
(43.5910)
|
40.409
(42.0560)
|
38.232
(41.0296)
|
31.975
(39.4910)
|
| Week 8, n=250, 20, 84, 83, 77, 71, 231 |
42.058
(41.2168)
|
34.290
(42.8300)
|
33.029
(41.0867)
|
44.118
(41.6682)
|
42.918
(42.8354)
|
34.811
(39.3585)
|
32.357
(39.9221)
|
| Week 9, n=244, 20, 82, 81, 76, 71, 229 |
39.268
(40.5300)
|
32.145
(44.6657)
|
32.759
(39.2972)
|
42.505
(41.2121)
|
39.476
(42.2376)
|
36.823
(42.3513)
|
33.606
(39.4690)
|
| Week 10, n=241, 20, 81, 80, 73, 71, 227 |
40.608
(41.0492)
|
35.000
(42.3430)
|
32.456
(40.7192)
|
43.396
(42.3040)
|
41.492
(42.1984)
|
37.024
(41.2291)
|
33.483
(40.1924)
|
| Week 11, n=241, 20, 79, 80, 73, 71, 226 |
39.701
(41.9689)
|
38.575
(44.2366)
|
35.624
(42.6625)
|
42.859
(41.7845)
|
39.337
(42.3061)
|
39.841
(43.7237)
|
33.127
(39.1842)
|
| Week 12, n=240, 20, 78, 80, 73, 70, 225 |
41.390
(40.8871)
|
39.415
(45.0442)
|
37.369
(40.2613)
|
41.300
(39.8199)
|
39.981
(40.8296)
|
42.236
(42.1567)
|
33.906
(38.4851)
|
| Over 12 Week, n=273, 21, 91, 91, 86, 83, 268 |
39.743
(36.8957)
|
35.533
(39.0694)
|
33.590
(36.6456)
|
40.441
(37.6285)
|
39.631
(36.5157)
|
35.820
(34.6377)
|
32.743
(33.9362)
|
| Title | Plasma Concentration of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed for concentrations of Nemiralisb. Pharmacokinetic (PK) Population consists of all participants in the Safety population who had at least 1 non-missing PK assessment (Non-quantifiable [NQ] values will be considered as non-missing values). Participants were summarized according to the treatment that they actually received. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Day 14, Pre-dose, n=2, 19, 24, 16, 18, 69 |
113.6
(6)
|
62.0
(46)
|
142.8
(44)
|
416.0
(59)
|
687.3
(53)
|
1069.6
(70)
|
| Day 14, 0-1 hour, n=4, 19, 24, 15, 18, 67 |
54.9
(43)
|
109.9
(51)
|
253.7
(73)
|
767.6
(71)
|
1492.0
(59)
|
1972.0
(110)
|
| Day 14, >1-6 hours, n=4, 20, 23, 15, 18, 65 |
35.0
(57)
|
93.1
(58)
|
231.8
(53)
|
657.0
(61)
|
1146.7
(56)
|
1622.7
(90)
|
| Day 28, Pre-dose, n=2, 18, 23, 16, 16, 67 |
23.6
(24)
|
60.5
(45)
|
129.4
(46)
|
315.6
(85)
|
528.3
(110)
|
937.6
(101)
|
| Day 28, 0-1 hour, n=3, 19, 23, 16, 15, 63 |
36.2
(26)
|
104.9
(70)
|
253.3
(52)
|
807.0
(66)
|
1552.2
(83)
|
1717.6
(114)
|
| Day 28, >1-6 hours, n=3, 18, 23, 16, 14, 64 |
28.1
(15)
|
85.4
(40)
|
211.4
(41)
|
598.8
(39)
|
1079.5
(80)
|
1388.1
(101)
|
| Title | Area Under the Concentration Time Curve (AUC) From Time Zero to 24 Hours [AUC(0-24)] of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Geometric Mean (Geometric Coefficient of Variation) [Hours*picograms per milliliter] |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Title | AUC From Time Zero to Time 't' [AUC(0-t)] of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Geometric Mean (Geometric Coefficient of Variation) [Hours*picograms per milliliter] |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Title | Maximum Observed Plasma Drug Concentration (Cmax) of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Geometric Mean (Geometric Coefficient of Variation) [Picograms per milliliter] |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Title | Time to Reach Cmax (Tmax) of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Median (Full Range) [Hours] |
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
| Title | Plasma Drug Concentration at Pre-dose (Ctrough) of Nemiralisib |
|---|---|
| Description | Plasma samples were collected at indicated time points and analyzed. |
| Time Frame | Pre-dose, 0-1 hour, >1-6 hours post-dose on Days 14 and 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PK Population. |
| Arm/Group Title | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 5 | 22 | 24 | 19 | 20 | 73 |
| Geometric Mean (Geometric Coefficient of Variation) [Picograms per milliliter] |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Title | Number of Participants Reporting Non-serious Adverse Events (Non-SAEs), SAEs and AE of Special Interest (AESI) |
|---|---|
| Description | An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect and other important medical events. Safety Population consists of all randomized participants who received at least one dose of study treatment. Participants were summarized according to treatment that they actually received. |
| Time Frame | Up to Week 24 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Any non-SAE |
31
11.2%
|
1
4.5%
|
14
15.4%
|
19
20.7%
|
25
27.8%
|
36
40.4%
|
101
36.3%
|
| Any SAE |
23
8.3%
|
2
9.1%
|
9
9.9%
|
13
14.1%
|
16
17.8%
|
6
6.7%
|
26
9.4%
|
| Any AESI |
9
3.3%
|
0
0%
|
10
11%
|
10
10.9%
|
21
23.3%
|
29
32.6%
|
93
33.5%
|
| Title | Number of Participants With Worst Case Post Baseline Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP) and Pulse Rate |
|---|---|
| Description | The DBP, SBP and pulse rate were measured with participants seated at least 5 minutes before the assessments. Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value. |
| Time Frame | Up to Week 16 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. Only those participants with data available at the specified data points were analyzed. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 271 | 21 | 91 | 92 | 88 | 88 | 266 |
| DBP, To low |
8
2.9%
|
3
13.6%
|
3
3.3%
|
0
0%
|
4
4.4%
|
4
4.5%
|
7
2.5%
|
| DBP, To within range/no change |
260
94.2%
|
17
77.3%
|
85
93.4%
|
91
98.9%
|
79
87.8%
|
82
92.1%
|
256
92.1%
|
| DBP, To high |
3
1.1%
|
1
4.5%
|
3
3.3%
|
1
1.1%
|
5
5.6%
|
2
2.2%
|
3
1.1%
|
| Pulse rate, To low |
1
0.4%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Pulse rate,To within range/no change |
265
96%
|
21
95.5%
|
84
92.3%
|
90
97.8%
|
82
91.1%
|
83
93.3%
|
258
92.8%
|
| Pulse rate, To high |
5
1.8%
|
0
0%
|
7
7.7%
|
2
2.2%
|
6
6.7%
|
5
5.6%
|
8
2.9%
|
| SBP, To low |
11
4%
|
1
4.5%
|
5
5.5%
|
3
3.3%
|
2
2.2%
|
3
3.4%
|
8
2.9%
|
| SBP, To withinn range/no change |
250
90.6%
|
18
81.8%
|
83
91.2%
|
82
89.1%
|
79
87.8%
|
80
89.9%
|
239
86%
|
| SBP, To high |
10
3.6%
|
2
9.1%
|
3
3.3%
|
7
7.6%
|
8
8.9%
|
6
6.7%
|
19
6.8%
|
| Title | Number of Participants With Abnormal Electrocardiogram (ECG) Findings |
|---|---|
| Description | A single 12-lead ECG with a 15-second rhythm strip was obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and corrected QT (QTc) intervals. Abnormal ECG findings are presented. |
| Time Frame | Screening, Days 14, 84, 112 and at early withdrawal |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Screening |
93
33.7%
|
10
45.5%
|
25
27.5%
|
37
40.2%
|
28
31.1%
|
21
23.6%
|
86
30.9%
|
| Day 14 |
88
31.9%
|
8
36.4%
|
24
26.4%
|
33
35.9%
|
29
32.2%
|
18
20.2%
|
74
26.6%
|
| Day 84 |
79
28.6%
|
8
36.4%
|
22
24.2%
|
27
29.3%
|
24
26.7%
|
18
20.2%
|
64
23%
|
| Day 112 |
77
27.9%
|
11
50%
|
28
30.8%
|
28
30.4%
|
25
27.8%
|
20
22.5%
|
75
27%
|
| Early withdrawal |
3
1.1%
|
0
0%
|
2
2.2%
|
1
1.1%
|
3
3.3%
|
1
1.1%
|
4
1.4%
|
| Title | Number of Participants With Worst Case Post Baseline Clinical Chemistry Values |
|---|---|
| Description | Blood samples were collected for the analysis of clinical chemistry parameters including: blood urea nitrogen (BUN), creatinine (Crt), glucose (Glu), potassium (Pot), sodium (Sod), calcium (Cal), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total and direct bilirubin, total protein and albumin (Alb). Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value. |
| Time Frame | Upto Week 16 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Alb,To low, n=266, 21, 91, 90, 87, 85, 263 |
2
0.7%
|
0
0%
|
0
0%
|
0
0%
|
1
1.1%
|
1
1.1%
|
2
0.7%
|
| Alb,w/in range/no change,n=266,21,91,90,87,85,263 |
264
95.7%
|
21
95.5%
|
90
98.9%
|
90
97.8%
|
85
94.4%
|
84
94.4%
|
261
93.9%
|
| Alb,To high,n=266,21,91,90,87,85,263 |
0
0%
|
0
0%
|
1
1.1%
|
0
0%
|
1
1.1%
|
0
0%
|
0
0%
|
| Cal,To low, n=266, 21, 90, 90, 87, 85, 263 |
1
0.4%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
1.1%
|
1
0.4%
|
| Cal,w/in range/no change,n=266,21,90,90,87,85,263 |
265
96%
|
21
95.5%
|
90
98.9%
|
90
97.8%
|
87
96.7%
|
84
94.4%
|
262
94.2%
|
| Cal,To high, n=266,21,90,90,87,85,263 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Crt,To low, n=266, 21, 91, 90, 87, 85, 263 |
27
9.8%
|
3
13.6%
|
10
11%
|
7
7.6%
|
4
4.4%
|
9
10.1%
|
32
11.5%
|
| Crt,w/in range/no change,n=266,21,91,90,87,85,263 |
237
85.9%
|
18
81.8%
|
81
89%
|
82
89.1%
|
80
88.9%
|
76
85.4%
|
231
83.1%
|
| Crt,To high, n=266,21,91,90,87,85,263 |
2
0.7%
|
0
0%
|
0
0%
|
1
1.1%
|
3
3.3%
|
0
0%
|
0
0%
|
| Glu,To low, n=266, 21, 91, 90, 87, 85, 263 |
0
0%
|
0
0%
|
0
0%
|
1
1.1%
|
0
0%
|
0
0%
|
0
0%
|
| Glu,w/in range/no change,n=266,21,91,90,87,85,263 |
266
96.4%
|
21
95.5%
|
91
100%
|
89
96.7%
|
87
96.7%
|
85
95.5%
|
263
94.6%
|
| Glu,To high, n=266,21,91,90,87,85,263 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Pot,To low, n=266, 21, 90, 90, 87, 85, 263 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Pot,w/in range/no change,n=266,21,90,90,87,85,263 |
264
95.7%
|
21
95.5%
|
90
98.9%
|
90
97.8%
|
86
95.6%
|
84
94.4%
|
262
94.2%
|
| Pot,To high, n=266,21,90,90,87,85,263 |
2
0.7%
|
0
0%
|
0
0%
|
0
0%
|
1
1.1%
|
1
1.1%
|
1
0.4%
|
| Sod,To low, n=266, 21, 91, 90, 87, 85, 263 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Sod,w/in range/no change,n=266,21,91,90,87,85,263 |
266
96.4%
|
21
95.5%
|
91
100%
|
90
97.8%
|
87
96.7%
|
85
95.5%
|
263
94.6%
|
| Sod,To high, n=266,21,91,90,87,85,263 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| BUN,To low, n=266, 21, 91, 90, 87, 85, 263 |
7
2.5%
|
0
0%
|
3
3.3%
|
2
2.2%
|
2
2.2%
|
3
3.4%
|
6
2.2%
|
| BUN,w/in range/no change,n=266,21,91,90,87,85,263 |
256
92.8%
|
21
95.5%
|
88
96.7%
|
86
93.5%
|
85
94.4%
|
82
92.1%
|
253
91%
|
| BUN,To high, n=266,21,91,90,87,85,263 |
3
1.1%
|
0
0%
|
0
0%
|
2
2.2%
|
0
0%
|
0
0%
|
4
1.4%
|
| Title | Number of Participants With Worst Case Post Baseline Hematology Values |
|---|---|
| Description | Blood samples were collected for the analysis of hematology parameters including: platelets (Pla), red blood cells count, Hemoglobin (Hb), Hematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), percentage reticulocytes, neutrophils (Neu), lymphocytes (Lym), monocytes, eosinophils, leukocytes (Leu) and basophils. Participants are counted in the worst case category if their value changes to (low, within range or no change, or high). Participants whose value category was unchanged (e.g., High to High), or whose value became within range, are recorded in the "To w/in Range or No Change" category. Participants are counted twice if the participant has values that changed "To Low" and "To High", so the percentages may not add to 100%. Participants with missing baseline value are assumed to have within range value. |
| Time Frame | Upto Week 16 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Hb,To low, n=260, 20, 90, 90, 84, 81, 254 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Hb,w/in range/no change,n=260,20,90,90,84,81,254 |
260
94.2%
|
20
90.9%
|
90
98.9%
|
90
97.8%
|
84
93.3%
|
81
91%
|
253
91%
|
| Hb,To high,n=260, 20, 90, 90, 84, 81, 254 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
0.4%
|
| Leu,To low,n=259, 20, 90, 90, 83, 78, 251 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Leu,w/in range/no change,n=259,20,90,90,83,78,251 |
211
76.4%
|
16
72.7%
|
81
89%
|
74
80.4%
|
63
70%
|
62
69.7%
|
201
72.3%
|
| Leu,To high, n=259,20,90,90,83,78,251 |
48
17.4%
|
4
18.2%
|
9
9.9%
|
16
17.4%
|
20
22.2%
|
16
18%
|
50
18%
|
| Lym,To low, n=256, 20, 85, 88, 82, 77, 249 |
8
2.9%
|
1
4.5%
|
6
6.6%
|
7
7.6%
|
7
7.8%
|
2
2.2%
|
11
4%
|
| Lym,w/in range/no change,n=256,20,85,88,82,77,249 |
239
86.6%
|
19
86.4%
|
79
86.8%
|
76
82.6%
|
70
77.8%
|
73
82%
|
226
81.3%
|
| Lym,To high,n=256,20,85,88,82,77,249 |
9
3.3%
|
0
0%
|
0
0%
|
5
5.4%
|
5
5.6%
|
2
2.2%
|
12
4.3%
|
| Neu, To low, n=256,20,85,88,82,77,249 |
3
1.1%
|
0
0%
|
1
1.1%
|
1
1.1%
|
0
0%
|
0
0%
|
2
0.7%
|
| Neu,w/in range/no change,n=256,20,85,88,82,77,249 |
215
77.9%
|
17
77.3%
|
73
80.2%
|
76
82.6%
|
68
75.6%
|
60
67.4%
|
213
76.6%
|
| Neu,To high, n=256,20,85,88,82,77,249 |
38
13.8%
|
3
13.6%
|
11
12.1%
|
11
12%
|
14
15.6%
|
17
19.1%
|
34
12.2%
|
| Pla,To low, n=253, 19, 88, 90, 84, 78, 245 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Pla,w/in range/no change,n=253,19,88,90,84,78,245 |
253
91.7%
|
19
86.4%
|
88
96.7%
|
90
97.8%
|
84
93.3%
|
78
87.6%
|
245
88.1%
|
| Pla,To high, n=253,19,88,90,84,78,245 |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Title | Number of Participants Reporting COPD Exacerbations |
|---|---|
| Description | Participants reporting acute COPD exacerbations during the study period has been presented. |
| Time Frame | Up to Week 16 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population. |
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. |
| Measure Participants | 276 | 22 | 91 | 92 | 90 | 89 | 278 |
| Count of Participants [Participants] |
8
2.9%
|
1
4.5%
|
6
6.6%
|
4
4.3%
|
4
4.4%
|
3
3.4%
|
17
6.1%
|
Adverse Events
| Time Frame | Non-serious AEs and SAEs were collected up to Week 24 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | Non-serious AEs and SAEs were summarized for the Safety Population. | |||||||||||||
| Arm/Group Title | Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg | |||||||
| Arm/Group Description | Participants were administered a single oral inhalation of placebo via ELLIPTA dry powder inhaler (DPI) once daily in the morning for 12 weeks. Albuterol (salbutamol) metered-dose inhaler (MDI) or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 12.5 micrograms (mcg) nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 50 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 100 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 250 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 500 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | Participants were administered a single oral inhalation of 750 mcg nemiralisib via ELLIPTA DPI once daily in the morning for 12 weeks. Albuterol (salbutamol) MDI or nebules were also provided to all participants as rescue medication. | |||||||
All Cause Mortality |
||||||||||||||
| Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1/276 (0.4%) | 0/22 (0%) | 3/91 (3.3%) | 1/92 (1.1%) | 0/90 (0%) | 0/89 (0%) | 1/278 (0.4%) | |||||||
Serious Adverse Events |
||||||||||||||
| Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 23/276 (8.3%) | 2/22 (9.1%) | 9/91 (9.9%) | 13/92 (14.1%) | 16/90 (17.8%) | 6/89 (6.7%) | 26/278 (9.4%) | |||||||
| Blood and lymphatic system disorders | ||||||||||||||
| Anaemia | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Cardiac disorders | ||||||||||||||
| Angina unstable | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 2/90 (2.2%) | 2 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Acute myocardial infarction | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Myocardial ischaemia | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 1/89 (1.1%) | 1 | 0/278 (0%) | 0 |
| Atrial fibrillation | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Atrioventricular block | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Bradycardia | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Cardiac arrest | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Cardiac failure congestive | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Myocardial infarction | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Sinus arrhythmia | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Ventricular tachycardia | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 1/89 (1.1%) | 1 | 0/278 (0%) | 0 |
| Gastrointestinal disorders | ||||||||||||||
| Enterocele | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Haematochezia | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 1/89 (1.1%) | 1 | 0/278 (0%) | 0 |
| Pancreatitis acute | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Small intestinal obstruction | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| General disorders | ||||||||||||||
| Non-cardiac chest pain | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Swelling | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Hepatobiliary disorders | ||||||||||||||
| Cholelithiasis | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Bile duct stone | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Infections and infestations | ||||||||||||||
| Pneumonia | 4/276 (1.4%) | 4 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 2/92 (2.2%) | 2 | 3/90 (3.3%) | 3 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Influenza | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 1/92 (1.1%) | 1 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Diverticulitis | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Cystitis klebsiella | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Infective exacerbation of chronic obstructive airways disease | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Respiratory syncytial virus infection | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Sepsis | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||||||||||||
| Contusion | 1/276 (0.4%) | 2 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Fall | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Hip fracture | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Wound dehiscence | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Investigations | ||||||||||||||
| Alanine aminotransferase increased | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 1/89 (1.1%) | 1 | 0/278 (0%) | 0 |
| Blood bilirubin increased | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 1/89 (1.1%) | 1 | 0/278 (0%) | 0 |
| C-reactive protein increased | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Hepatic enzyme increased | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Metabolism and nutrition disorders | ||||||||||||||
| Dehydration | 0/276 (0%) | 0 | 1/22 (4.5%) | 1 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Hyperglycaemia | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Metabolic acidosis | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||||||||||||
| Intervertebral disc protrusion | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||||
| Bronchial carcinoma | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 1/91 (1.1%) | 1 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Adenocarcinoma of colon | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Lung neoplasm malignant | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Neuroendocrine tumour | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Squamous cell carcinoma of lung | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Nervous system disorders | ||||||||||||||
| Intracranial hematoma | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Psychiatric disorders | ||||||||||||||
| Conversion disorder | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Renal and urinary disorders | ||||||||||||||
| Acute kidney injury | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Renal impairment | 0/276 (0%) | 0 | 1/22 (4.5%) | 1 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||||||||||
| Chroni obstructive pulmonary disease | 8/276 (2.9%) | 8 | 1/22 (4.5%) | 1 | 6/91 (6.6%) | 7 | 4/92 (4.3%) | 4 | 4/90 (4.4%) | 5 | 3/89 (3.4%) | 3 | 17/278 (6.1%) | 17 |
| Acute respiratory failure | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Bronchospasm | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Dyspnoea | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Lung disorder | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Pneumothorax | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Pulmonary embolism | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 1/90 (1.1%) | 1 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Pulmonary mass | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Respiratory failure | 1/276 (0.4%) | 1 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Wheezing | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Vascular disorders | ||||||||||||||
| Arterial thrombosis | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 1/92 (1.1%) | 1 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 0/278 (0%) | 0 |
| Hypertension | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
| Hypotension | 0/276 (0%) | 0 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 0/92 (0%) | 0 | 0/90 (0%) | 0 | 0/89 (0%) | 0 | 1/278 (0.4%) | 1 |
Other (Not Including Serious) Adverse Events |
||||||||||||||
| Placebo | Nemiralisib 12.5 mcg | Nemiralisib 50 mcg | Nemiralisib 100 mcg | Nemiralisib 250 mcg | Nemiralisib 500 mcg | Nemiralisib 750 mcg | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 31/276 (11.2%) | 1/22 (4.5%) | 14/91 (15.4%) | 19/92 (20.7%) | 25/90 (27.8%) | 36/89 (40.4%) | 101/278 (36.3%) | |||||||
| Nervous system disorders | ||||||||||||||
| Headache | 23/276 (8.3%) | 41 | 1/22 (4.5%) | 1 | 6/91 (6.6%) | 8 | 8/92 (8.7%) | 10 | 4/90 (4.4%) | 5 | 2/89 (2.2%) | 2 | 15/278 (5.4%) | 18 |
| Respiratory, thoracic and mediastinal disorders | ||||||||||||||
| Cough | 13/276 (4.7%) | 13 | 0/22 (0%) | 0 | 10/91 (11%) | 12 | 11/92 (12%) | 17 | 23/90 (25.6%) | 27 | 31/89 (34.8%) | 58 | 96/278 (34.5%) | 141 |
| Oropharyngeal pain | 2/276 (0.7%) | 2 | 0/22 (0%) | 0 | 0/91 (0%) | 0 | 2/92 (2.2%) | 2 | 3/90 (3.3%) | 3 | 5/89 (5.6%) | 5 | 2/278 (0.7%) | 2 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Results Point of Contact
| Name/Title | GSK Response Center |
|---|---|
| Organization | GlaxoSmithKline |
| Phone | 866-435-7343 |
| GSKClinicalSupportHD@gsk.com |
Responsible Party:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT03345407
Other Study ID Numbers:
- 200879
- 2017-001074-42
First Posted:
Nov 17, 2017
Last Update Posted:
Jul 14, 2021
Last Verified:
Jul 1, 2021